Inspire Medical’s Stock Soars 28% After CMS Boosts Sleep Apnea Implant Payments
Shares of Inspire Medical Systems climbed sharply after U.S. health authorities raised reimbursement rates for its sleep apnea implants. The company’s stock jumped 28% following the announcement by the Centers for Medicare & Medicaid Services (CMS).
The CMS decision significantly increased payments for Inspire’s devices. Hospital reimbursements rose from about $30,500 to roughly $40,500. Outpatient surgery centers saw an even larger boost, with payments jumping from $26,800 to $42,400—an increase of nearly 50%.
The CMS reimbursement hike has already lifted Inspire’s share price and prompted analyst upgrades. With potential price increases from the company itself, revenue growth may accelerate in the next few years. Health insurance providers in multiple markets are now adjusting their own payment structures in response.
